Personalized treatment options for thyroid cancer: current perspectives

References

• Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med 2013;10(6):565–576. doi:10.2217/pme.13.57
   Google Scholar
• Movafagh A. Personalised medicine in modern era. Asian Pac J Cancer Biol. 2016;1:2.
   Google Scholar
• Turnbull AK. Personalized medicine in cancer: where are we today? Future Oncol. 2015;11(20):2795–2798. doi:10.2217/fon.15.20426344657
   PubMed Web of Science ®Google Scholar
• Keller EF. The century beyond the gene. J Biosci. 2005;30(1):3–10.15824435
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Rev Cancer. 2013;13(10):714. doi:10.1038/nrc359924060863
   PubMed Web of Science ®Google Scholar
• Giaccone G, Pinedo HM. Drug resistance. Oncologist. 1996;1(1 & 2):82–87.10387972
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• Larijani B, Mohagheghi MA, Bastanhagh MH, et al. Primary thyroid malignancies in Tehran, Iran. Med principles pract. 2005;14(6):396–400. doi:10.1159/000088112
   Web of Science ®Google Scholar
• Haghpanah V, Soliemanpour B, Heshmat R, et al. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80. doi:10.4103/0019-509X.2588916790945
   PubMedGoogle Scholar
• Larijani B, Shirzad M, Mohagheghi M, et al. Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR). Asian Pac J Cancer Prev. 2004;5(1):36–39.15075002
   PubMedGoogle Scholar
• Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer. Ann Clin Pathol. 2015;3(1):1045.
   Google Scholar
• Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24(13):3059–3068. doi:10.1158/1078-0432.CCR-18-037329615459
   PubMed Web of Science ®Google Scholar
• Lin J-D, Chao T-C. Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm. 2005;20(6):648–661. doi:10.1089/cbr.2005.20.64816398617
   PubMed Web of Science ®Google Scholar
• Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20(8):863–871. doi:10.1089/thy.2009.041720615131
   PubMed Web of Science ®Google Scholar
• Agaimy A, Terracciano L, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62(7):613–616. doi:10.1136/jcp.2009.06455019561230
   PubMed Web of Science ®Google Scholar
• Kim M-J, Kim SK, Park HJ, et al. PDGFRA promoter polymorphisms are associated with the risk of papillary thyroid cancer. Mol Med Rep. 2012;5(5):1267–1270. doi:10.3892/mmr.2012.78422327316
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016;7(22):32318. doi:10.18632/oncotarget.869827086918
   PubMedGoogle Scholar
• Ameur N, Lacroix L, Motte N, et al. Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. Int J cancer. 2009;124(3):751–753. doi:10.1002/ijc.2399919003996
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. doi:10.5114/wo.2014.4713625691825
   PubMedGoogle Scholar
• Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8(1):83–95. doi:10.1586/14737159.8.1.8318088233
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–262. doi:10.1677/erc.1.097815947100
   PubMed Web of Science ®Google Scholar
• Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92(11):2032–2038. doi:10.1038/sj.bjc.660259815928660
   PubMed Web of Science ®Google Scholar
• Kim WW, Ha TK, Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head Neck Surg. 2018;47(1):4. doi:10.1186/s40463-017-0247-629316976
   PubMed Web of Science ®Google Scholar
• Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol 2009;5(1):105–116. doi:10.2217/14796694.5.1.105
   Google Scholar
• Xing M. Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer. BMC Med. 2016;14(1):12. doi:10.1186/s12916-016-0559-926817707
   PubMed Web of Science ®Google Scholar
• Nozhat Z, Hedayati M. PI3K/AKT pathway and its mediators in thyroid carcinomas. Mol Diagn Ther. 2016;20(1):13–26. doi:10.1007/s40291-015-0175-y26597586
   PubMed Web of Science ®Google Scholar
• Nagy R, Ganapathi S, Comeras I, et al. Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 2011;21(5):505–510. doi:10.1089/thy.2010.036521417916
   PubMed Web of Science ®Google Scholar
• Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol. 2009;4(1):41. doi:10.1186/1746-1596-4-4119930726
   PubMed Web of Science ®Google Scholar
• García-Rostán G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199–10207. doi:10.1158/0008-5472.CAN-04-425916288007
   PubMed Web of Science ®Google Scholar
• Wu G, Mambo E, Guo Z, et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005;90(8):4688–4693. doi:10.1210/jc.2004-228115928251
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nature Rev Cancer. 2013;13(3):184. doi:10.1038/nrc343123429735
   PubMed Web of Science ®Google Scholar
• Lin Y, Jiang X, Shen Y, et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer. 2009;16(1):301–310. doi:10.1677/ERC-08-016718852163
   PubMed Web of Science ®Google Scholar
• Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and PI3K/Akt and MAP kinase pathways in anaplastic and follicular thyroid cancers. Med Baltimore. 2008;1500:21287.
   Google Scholar
• Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simões M. Prognostic biomarkers in thyroid cancer. Virchows Archiv. 2014;464(3):333–346. doi:10.1007/s00428-013-1521-224487783
   PubMed Web of Science ®Google Scholar
• Xing MM Genetic amplification of IQGAP1 in cancer. Google Patents; 2015.
   Google Scholar
• Liu Z, Xie Liu D, Bojdani E, El-Naggar AK, Vasko V, Xing M. IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res. 2010 clincanres. 1627.2010. doi:10.1158/1078-0432.CCR-10-1627
   Web of Science ®Google Scholar
• Nakazawa T, Kondo T, Kobayashi Y, et al. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine‐rich country (Japan). Cancer. 2005;104(5):943–951. doi:10.1002/cncr.2127016015630
   PubMed Web of Science ®Google Scholar
• Eberhardt NL, Grebe SK, McIver B, Reddi HV. The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321(1):50–56. doi:10.1016/j.mce.2009.10.01319883731
   PubMed Web of Science ®Google Scholar
• Castro P, Rebocho A, Soares R, et al. PAX8-PPAR γ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):213–220. doi:10.1210/jc.2005-133616219715
   PubMed Web of Science ®Google Scholar
• Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol. 2011;46(3):R73-81. doi:10.1530/JME-10-0150
   Web of Science ®Google Scholar
• Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13):3698–3701.12097277
   PubMed Web of Science ®Google Scholar
• Mohammadi-asl J, Larijani B, Khorgami Z, et al. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma. Med Oncol. 2011;28(4):1123–1128. doi:10.1007/s12032-010-9587-z20535589
   PubMed Web of Science ®Google Scholar
• Khatami F, Tavangar SM. Genetic and epigenetic of medullary thyroid cancer. Iran Biomed J. 2018;22(3):142.29126344
   PubMedGoogle Scholar
• Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 2003;63(9):2316–2321.12727856
   PubMed Web of Science ®Google Scholar
• Hoque M, Rosenbaum E, Westra W, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005;90(7):4011–4018. doi:10.1210/jc.2005-031315840741
   PubMed Web of Science ®Google Scholar
• Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 2006;16(1):17–23. doi:10.1089/thy.2006.16.1716487009
   PubMed Web of Science ®Google Scholar
• Khatami F, Larijani B, Heshmat R, et al. Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS One. 2017;12(9):e0184892. doi:10.1371/journal.pone.018489228926589
   PubMed Web of Science ®Google Scholar
• Cai -L-L, Liu G-Y, Tzeng C-M. Genome-wide DNA methylation profiling and its involved molecular pathways from one individual with thyroid malignant/benign tumor and hyperplasia: a case report. Medicine. 2016;95:35. doi:10.1097/MD.0000000000004864
   Web of Science ®Google Scholar
• Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13(2):497–508. doi:10.1677/erc.1.0120916728577
   PubMed Web of Science ®Google Scholar
• Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18(7):2035–2041. doi:10.1245/s10434-011-1733-021537871
   PubMed Web of Science ®Google Scholar
• Ramírez-Moya J, Wert-Lamas L, Santisteban P. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN. Oncogene. 2018;37(25):3369–3383. doi:10.1038/s41388-017-0088-9
   Web of Science ®Google Scholar
• Natanzi MM, Pasalar P, Kamalinejad M, et al. Effect of aqueous extract of Elaeagnus angustifolia fruit on experimental cutaneous wound healing in rats. Acta Med Iran. 2012;50(9):589–596.23165807
   PubMedGoogle Scholar
• Alimoghaddam K, Shariftabrizi A, Tavangar M, et al. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma. 2006;47(1):81–88. doi:10.1080/1042819050030037316321832
   PubMed Web of Science ®Google Scholar
• Parvizi MR, Parviz M, Tavangar SM, et al. Protective effect of magnesium on renal function in STZ-induced diabetic rats. J Diabetes Metab Disord. 2014;13(1):84. doi:10.1186/s40200-014-0084-325197628
   PubMedGoogle Scholar
• Tavangar SM, Larijani B, Mahta A, Hosseini SMA, Mehrazine M, Bandarian F. Craniopharyngioma: a clinicopathological study of 141 cases. Endocr Pathol. 2004;15(4):339–344.15681858
   PubMed Web of Science ®Google Scholar
• Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56(4):333–339. doi:10.1159/00033995922846422
   PubMed Web of Science ®Google Scholar
• Omidfar K, Moinfar Z, Sohi AN, et al. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest. 2009;38(2):165–180. doi:10.1080/0882013090273599819330625
   PubMed Web of Science ®Google Scholar
• Haghpanah V, Shooshtarizadeh P, Heshmat R, Larijani B, Tavangar SM. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl Immunohistochem Mol Morphol. 2006;14(4):422–425. doi:10.1097/01.pai.0000213100.88074.b817122639
   PubMedGoogle Scholar
• Saffar H, Sanii S, Emami B, et al. Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors. Pathol Res Pract. 2013;209(3):195–199. doi:10.1016/j.prp.2012.06.01123384723
   PubMed Web of Science ®Google Scholar
• Haddadi-Nezhad S, Larijani B, Tavangar SM, Nouraei SM. Comparison of fine-needle-nonaspiration with fine-needle-aspiration technique in the cytologic studies of thyroid nodules. Endocr Pathol. 2003;14(4):369–373.14739493
   PubMed Web of Science ®Google Scholar
• Sanii S, Saffar H, Tabriz HM, Qorbani M, Haghpanah V, Tavangar SM. Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev. 2012;13(5):2175–2178. doi:10.7314/apjcp.2012.13.5.217522901190
   PubMedGoogle Scholar
• Tabriz HM, Adabi K, Lashkari A, et al. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Pathol Res Pract. 2009;205(2):83–87. doi:10.1016/j.prp.2008.08.00718996649
   PubMed Web of Science ®Google Scholar
• Zhang M, Lin O. Molecular testing of thyroid nodules: a review of current available tests for fine-needle aspiration specimens. Arch Pathol Lab Med. 2016;140(12):1338–1344. doi:10.5858/arpa.2016-0100-RA27557410
   PubMed Web of Science ®Google Scholar
• Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010;95(12):5296–5304. doi:10.1210/jc.2010-108720826580
   PubMed Web of Science ®Google Scholar
• Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705–715. doi:10.1056/NEJMoa120320822731672
   PubMed Web of Science ®Google Scholar
• Marti JL, Avadhani V, Donatelli LA, et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. Ann Surg Oncol. 2015;22(12):3996–4001. doi:10.1245/s10434-015-4486-325862581
   PubMed Web of Science ®Google Scholar
• Duick DS, Klopper JP, Diggans JC, et al. The impact of benign gene expression classifier test results on the endocrinologist–patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012;22(10):996–1001. doi:10.1089/thy.2012.018022873825
   PubMed Web of Science ®Google Scholar
• Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1):20–28. doi:10.1016/j.mce.2009.10.01619897009
   PubMed Web of Science ®Google Scholar
• Pallante P, Battista S, Pierantoni GM, Fusco A. Deregulation of microRNA expression in thyroid neoplasias. Nature Rev Endocrinol. 2014;10(2):88. doi:10.1038/nrendo.2013.22324247220
   PubMed Web of Science ®Google Scholar
• Stokowy T, Wojtaś B, Krajewska J, et al. A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. Mol Cell Endocrinol. 2015;399:43–49. doi:10.1016/j.mce.2014.09.01725258301
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98(11):E1852–E1860. doi:10.1210/jc.2013-229223979959
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation sequencing assay. Cancer. 2014;120(23):3627–3634. doi:10.1002/cncr.2903825209362
   PubMed Web of Science ®Google Scholar
• Le Mercier M, D’haene N, De Nève N, et al. Next‐generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology. 2015;66(2):215–224. doi:10.1111/his.1246124834793
   PubMed Web of Science ®Google Scholar
• Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Int Med. 1996;156(19):2165–2172.8885814
   PubMedGoogle Scholar
• Higashi T, Kudo T, Kinuya S. Radioactive iodine (131 I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26(2):99–112. doi:10.1007/s12149-011-0553-422081274
   PubMed Web of Science ®Google Scholar
• Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers. Cancer. 1985;55(S9):2062–2071. doi:10.1002/1097-0142(19850501)55:9+<2062::aid-cncr2820551406>3.0.co;2-o3919920
   PubMed Web of Science ®Google Scholar
• Brierley JD, Tsang RW, editors. External‐beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol. 1999. Wiley Online Library. doi:10.1002/(SICI)1098-2388(199901/02)16:1<42::AID-SSU8>3.0.CO;2-4
   Google Scholar
• Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol. 2010;80(5):592–601. doi:10.1016/j.bcp.2010.05.00320471374
   PubMed Web of Science ®Google Scholar
• Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol. 2012;6:CMO. S7999. doi:10.4137/CMO.S7999
   Google Scholar
• Hoy SM. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Drugs. 2014;74(12):1435–1444. doi:10.1007/s40265-014-0265-x25056653
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Santini F, et al. Sorafenib and thyroid cancer. BioDrugs. 2013;27(6):615–628. doi:10.1007/s40259-013-0049-y23818056
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47–55. doi:10.1016/j.ctrv.2015.11.00326678514
   PubMed Web of Science ®Google Scholar
• Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs. 2013;73(12):1367–1376. doi:10.1007/s40265-013-0095-223881668
   PubMed Web of Science ®Google Scholar
• McGETTIGAN S. Dabrafenib: a new therapy for use in BRAF-mutated metastatic melanoma. J Adv Pract Oncol. 2014;5(3):211.25089220
   PubMedGoogle Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7. doi:10.1200/JCO.2017.73.678529072975
   PubMed Web of Science ®Google Scholar
• Jeelani S, Reddy RJ, Maheswaran T, Asokan G, Dany A, Anand B. Theranostics: a treasured tailor for tomorrow. J Pharm Bioallied Sci. 2014;6(Suppl 1):S6. doi:10.4103/0975-7406.13724925210387
   PubMedGoogle Scholar
• Oh J-R, Ahn B-C, Jeong SY, Lee S-W, Lee J. Radioiodine scan index: a simplified, quantitative treatment response parameter for metastatic thyroid carcinoma. Nucl Med Mol Imaging (2010). 2015;49(3):174–181. doi:10.1007/s13139-015-0335-3
   Google Scholar
• Kim D-H, Jung J-H, Son SH, et al. Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer. Nucl Med Mol Imaging (2010). 2014;48(1):55–62. doi:10.1007/s13139-013-0239-z
   Google Scholar
• Hong C, Ahn B-C, Jeong S, Lee S-W, Lee J. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Nuklearmedizin. 2013;52(04):121–129. doi:10.3413/Nukmed-0541-12-1123928981
   PubMedGoogle Scholar
• Lee JW, Min HS, Lee SM, Kwon HW, Chung J-K. Relations between pathological markers and radioiodine scan and 18 F-FDG PET/CT findings in papillary thyroid cancer patients with recurrent cervical nodal metastases. Nucl Med Mol Imaging (2010). 2015;49(2):127–134. doi:10.1007/s13139-015-0324-6
   Google Scholar
• Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. lancet Diabetes endocrinol. 2014;2(10):830–842. doi:10.1016/S2213-8587(14)70051-824898835
   PubMed Web of Science ®Google Scholar
• Micali S, Bulotta S, Puppin C, et al. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. BMC Cancer. 2014;14(1):303. doi:10.1186/1471-2407-14-30324884806
   PubMed Web of Science ®Google Scholar
• Plantinga TS, Heinhuis B, Gerrits D, et al. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014;99(7):E1368–E1375. doi:10.1210/jc.2014-117124712572
   PubMed Web of Science ®Google Scholar
• Wong K-P, Lang B-H-H. New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J Thyroid Res. 2012;2012:818204. doi:10.1155/2012/818204
   Google Scholar
• Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015;21(5):1028–1035. doi:10.1158/1078-0432.CCR-14-291525549723
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi:10.1056/NEJMoa171444829466156
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705–714. doi:10.1016/S1470-2045(18)30119-029606586
   PubMed Web of Science ®Google Scholar
• Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 2015;111(1):43–50. doi:10.1002/jso.2376825155423
   PubMed Web of Science ®Google Scholar
• Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–E1566. doi:10.1210/jc.2013-238323833040
   PubMed Web of Science ®Google Scholar
• Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603–610. doi:10.1530/ERC-13-021023766237
   PubMed Web of Science ®Google Scholar
• Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197(2):191–197. doi:10.1016/S1072-7515(03)00332-612892796
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42. doi:10.1056/NEJMoa07585318596272
   PubMed Web of Science ®Google Scholar
• Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623–632. doi:10.1056/NEJMoa120928823406027
   PubMed Web of Science ®Google Scholar
• Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation. Thyroid. 2013;23(10):1277–1283. doi:10.1089/thy.2013.005723489023
   PubMed Web of Science ®Google Scholar
• Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):713–722. doi:10.1016/j.beem.2009.08.00119942148
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708. doi:10.1200/JCO.2007.15.277718541897
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET–positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–5268. doi:10.1158/1078-0432.CCR-10-099420847059
   PubMed Web of Science ®Google Scholar
• Khatami F, Larijani B, Tavangar SM. Circulating tumor BRAF mutation and personalized thyroid cancer treatment. Asian Pacif j cancer prev. 2017;18(2):293. doi:10.22034/APJCP.2017.18.1.23
   Google Scholar
• Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–1282. doi:10.1016/S1470-2045(16)30166-827460442
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Ruffilli I, Centanni M, et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–208. doi:10.2174/157489281366618022011072929468981
   PubMed Web of Science ®Google Scholar
• Balmelli C, Railic N, Siano M, et al. Lenvatinib in advanced radioiodine-refractory thyroid cancer – a retrospective analysis of the Swiss Lenvatinib Named Patient Program. J Cancer. 2018;9(2):250–255. doi:10.7150/jca.2231829344270
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan673328596308
   PubMed Web of Science ®Google Scholar
• Barbolosi D, Summer I, Meille C, et al. Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine. Oncotarget. 2017;8(24):39167. doi:10.18632/oncotarget.1663728389624
   PubMedGoogle Scholar
• Liu Y, Gunda V, Zhu X, et al. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Proc National Acad Sci. 2016;113(28):7750–7755. doi:10.1073/pnas.1605841113
   Web of Science ®Google Scholar
• Pan Y, Liu P, Chen D, Dou L. Small interfering RNA (siRNA) against Slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin. Cancer Biomarkers. 2017;18(4):357–366. doi:10.3233/CBM-16019228128736
   PubMed Web of Science ®Google Scholar
• Fadda G, Rossi ED. Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol. 2011;55(5):389–400. doi:10.1159/00032902921986164
   PubMed Web of Science ®Google Scholar
• Khatami F, Larijani B, Tavangar SM. The presence of tumor extrachomosomal circular DNA (ecDNA) as a component of liquid biopsy in blood. Med Hypotheses. 2018;114:5–7. doi:10.1016/j.mehy.2018.02.01829602465
   PubMed Web of Science ®Google Scholar
• Khatami F, Tavangar SM. Liquid biopsy in thyroid cancer: new Insight. Int J Hematol Oncol Stem Cell Res. 2018;12(3):235.30595827
   PubMedGoogle Scholar
• Bardelli A. Medical research: personalized test tracks cancer relapse. Nature. 2017;545(7655):417. doi:10.1038/545417a28541318
   PubMed Web of Science ®Google Scholar
• Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(6):2084–2092. doi:10.1210/jc.2011-305922472564
   PubMed Web of Science ®Google Scholar